Skip to main content

Cervical Cancer Screening

Cervical cancer screening is a well-established preventive strategy that can reduce the lifetime risk of cervical cancer from up to 5% in unscreened populations to less than 0.5% with effective screening and treatment of precancers.[1] All major U.S. guideline organizations now endorse primary high-risk HPV (hrHPV) testing as the preferred screening method for most individuals — a major shift from cytology-based screening.[2][3]

Screening methods​

Three strategies are endorsed:[2]

  • Primary HPV testing (preferred) — uses an FDA-approved hrHPV test alone. Sensitivity for detecting precancer exceeds 90%, vs. 50–70% for cytology. A recent large RCT showed a 17% lower risk of invasive cervical cancer with primary HPV screening compared with cytology with reflex to HPV.[1][2]
  • Cotesting — HPV testing combined with cytology. Provides increased sensitivity and long-term negative predictive value vs. cytology alone, but adds limited incremental benefit over HPV testing alone since 97% of precancers are HPV-positive.[1][2]
  • Cytology alone (Pap test) — acceptable when HPV testing is unavailable. Requires more frequent screening (every 3 years) due to lower sensitivity.[2]

Current guideline recommendations by age​

AgeUSPSTFACS
<21 yearsNo screeningNo screening
21–24Cytology every 3 yearsNo screening before age 25
25–29Cytology every 3 yearsPrimary HPV every 5 years (clinician-collected) or 3 years (self-collected)
30–65Primary HPV every 5 years (preferred); cotesting every 5 years or cytology every 3 years acceptableSame — primary HPV every 5 years preferred
>65Discontinue with adequate prior negative resultsNegative primary HPV (preferred) or cotesting at ages 60 and 65 = discontinue
After hysterectomy with cervix removalNo screening if no history of CIN2+ or cervical cancerSame
[2][4][5]

Key points of agreement and divergence:

  • Under 21 years — no screening recommended by any guideline.[2][4]
  • Ages 21–24 — USPSTF recommends cytology every 3 years; ACS recommends no screening before age 25.[2]
  • Ages 25–29 — USPSTF continues cytology every 3 years; ACS recommends primary HPV testing every 5 years (clinician-collected) or every 3 years (self-collected).[2]
  • Ages 30–65 — both agree that primary HPV testing every 5 years is preferred. Cotesting every 5 years or cytology every 3 years are acceptable alternatives.[2]
  • Over 65 — screening can be discontinued with adequate prior negative results. ACS now recommends a forward-looking approach: negative primary HPV testing (preferred) or negative cotesting at ages 60 and 65.[2][5]
  • After hysterectomy with cervix removal — no screening if no history of CIN2+ or cervical cancer.[2][4]

HPV self-collection — a major recent advance​

The FDA approved the first self-collected vaginal specimens for HPV testing in clinical settings in May 2024, and the first at-home self-collection device (Teal Wand) in May 2025.[6][2]

  • Self-collected and clinician-collected samples show similar accuracy for detecting high-grade cervical lesions (pooled overall agreement ~89%).[2][6]
  • Clinician-collected specimens remain preferred because they allow reflex cytology from the same sample if HPV-positive. Self-collected specimens require a return visit for cytology if HPV-positive.[6]
  • After a negative self-collected HPV test, repeat screening is recommended in 3 years (vs. 5 years for clinician-collected) — a margin of safety while U.S. longitudinal data accrue.[2][6]
  • Self-collection is not appropriate for immunocompromised patients, those with HIV, DES exposure, history of cervical cancer, or those requiring cytology-based surveillance.[6][3]
  • HRSA guidelines effective January 2027 require insurance coverage of self-collected hrHPV testing without cost-sharing.[3]

Management of abnormal results — ASCCP risk-based framework​

The 2019 ASCCP guidelines introduced a paradigm shift from results-based to risk-based management, using the estimated risk of CIN3+ (CIN3, adenocarcinoma in situ, or cancer) to guide clinical action:[1][7]

Immediate CIN3+ riskRecommended action
<4%Surveillance (1, 3, or 5 years depending on result)
4–24%Colposcopy
25–59%Colposcopy or excisional treatment acceptable
≥60%Expedited treatment (excision without prior colposcopy) preferred
[1]

A prior negative HPV test within 5 years reduces the CIN3+ risk by approximately 50% for new low-grade abnormalities, potentially allowing deferral of colposcopy.[7][8] After treatment for CIN2 / CIN3, surveillance with HPV testing or cotesting at 3-year intervals is recommended for at least 25 years.[7]

Special populations​

More frequent screening is recommended for immunocompromised patients — those with HIV, solid-organ transplant, hematopoietic stem-cell transplant, systemic lupus erythematosus, inflammatory bowel disease, and those on immunosuppressive therapies.[2] These individuals should not use self-collection and require both HPV and cytology testing.[6] Screening recommendations apply regardless of HPV vaccination status or sexual history.[4][5]

Screening gaps and disparities​

Despite effective screening, over 50% of cervical cancers in the U.S. are diagnosed in individuals overdue for screening.[9] Up-to-date screening rates have declined to approximately 75% and have not rebounded post-pandemic.[6] Disparities persist among uninsured, rural, and racial / ethnic minority populations — making self-collection a particularly promising strategy for these groups.[6][10]

Cross-references​

References​

1. Perkins RB, Wentzensen N, Guido RS, Schiffman M. "Cervical cancer screening: a review." JAMA. 2023;330(6):547–558. doi:10.1001/jama.2023.13174

2. Wiser A, Quinlan JD. "Cervical cancer screening." Am Fam Physician. 2026;113(2):137–144.

3. Christine B, Bush M, Thurakal A, Sheehy AM. "New cervical cancer screening guidelines from the US Department of Health and Human Services." JAMA. 2026. doi:10.1001/jama.2025.26456

4. US Preventive Services Task Force, Curry SJ, Krist AH, et al. "Screening for cervical cancer: US Preventive Services Task Force recommendation statement." JAMA. 2018;320(7):674–686. doi:10.1001/jama.2018.10897

5. American Cancer Society. "Screening for cervical cancer." CA Cancer J Clin. 2026;76(1):e70049. doi:10.3322/caac.70049

6. Perkins RB, Wolf AMD, Church TR, et al. "Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: an update to the American Cancer Society cervical cancer screening guideline." CA Cancer J Clin. 2026;76(1):e70041. doi:10.3322/caac.70041

7. American College of Obstetricians and Gynecologists, Chelmow D. Updated Guidelines for Management of Cervical Cancer Screening Abnormalities. American College of Obstetricians and Gynecologists; 2024.

8. Espinosa K. "ASCCP management guidelines for abnormal cervical cancer screening." Am Fam Physician. 2024;109(3):275–276.

9. Winer RL, Lin J, Anderson ML, et al. "Strategies to increase cervical cancer screening with mailed human papillomavirus self-sampling kits: a randomized clinical trial." JAMA. 2023;330(20):1971–1981. doi:10.1001/jama.2023.21471

10. Montealegre JR, Hilsenbeck SG, Bulsara S, et al. "Self-collection for cervical cancer screening in a safety-net setting." JAMA Intern Med. 2025;185(9):1119–1127. doi:10.1001/jamainternmed.2025.2971